Research Paper Volume 15, Issue 7 pp 2734—2771
Comprehensive analysis reveals TSEN54 as a robust prognosis biomarker and promising immune-related therapeutic target for hepatocellular carcinoma
Figure 3. The TSEN54 promoter methylation level is correlated with clinicopathological features. (A) sample type; (B) stage; (C) grade; (D) lymph node metastasis; (E) TP53 mutation status; (F) patient’s gender. (G) The correlation between TSEN54 methylation and its mRNA expression.